Jie Chen currently is vice president of CMC Management at WuXi Biologics responsible for management of CMC operations and team in the US East Coast to support technical strategy alignment of internal efforts with client product development goals. Jie has over 20 year experiences in process development, protein characterization, formulation and manufacturing production fields for biological drugs with track record of scientific journal publications in bioprocessing areas. Prior to Joining WuXi Biologics, she served as Senior Director of Process Sciences at Dyax leading development programs from cell line development to GMP supply of clinical and commercial biologic drugs. During 16 years’ career at Dyax, Jie was in charge of building and managing process development teams, governing CMC programs, and overseeing CRO/CMO development and manufacturing activities. Post Dyax-Shire acquisition, Jie held the position of Process Development and CMC Director at Shire, managing CMC operations of both early and late stage development programs for legacy Dyax monoclonal antibody products. Jie worked also in several biotech companies in Cambridge, Massachusetts before Dyax. Jie Chen had a M.D. degree in internal medicine from School of Medicine, Xi'an Jiaotong University, received post-doctoral training at University of Pennsylvania, Philadelphia, PA, and obtained a M.S. degree in Physiology and Neurobiology from Rutgers University, Piscataway, NJ.